New case-based textbook explores complex pediatric colorectal care
25 February 2026
Rise in respiratory infections and measles outbreak: important infection prevention measures at the Montreal Children’s Hospital.
Read more
4 October 2024
As of November 1, 2024, a new medication called nirsevimab will be available in Quebec to prevent respiratory syncytial virus (RSV).
RSV is a common, highly contagious respiratory virus, infecting nearly all children by two years of age.
It is the most common cause of bronchiolitis and pneumonia in children less than one year of age.
A Quebec-based study found RSV was the most common virus (63.6 per cent) in children hospitalized for acute respiratory infection, with higher severity in children born prematurely and babies under six months of age (Papenburg et al, 2012).
Nirsevimab will be available at CLSCs and local points of service for:
How is it given?
Nirsevimab is administered at the start/during RSV season as an intramuscular injection, usually in the thigh muscle.
Where will it be given?
Don’t hesitate to book an appointment for your child!
New case-based textbook explores complex pediatric colorectal care
25 February 2026
Winter‑related injuries: MCH Trauma Centre issues safety reminder
24 February 2026
Celebrating Critical Care Transport Nurses at the MCH
18 February 2026
Psychoeducation: test your knowledge!
18 February 2026
Insightful words from a pediatric psychologist
2 February 2026
Roll up your sleeves! The MUHC blood drive is back!
16 January 2026
2025–2026 Accessibility Action Plan approved
16 January 2026
The MCH continues to ensure the protection of children
8 January 2026